Patents by Inventor Bruce Robert Blazar

Bruce Robert Blazar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF GVHD
    Publication number: 20220395501
    Abstract: The invention relates to treatment of graft versus host disease (GVHD) using compounds that inhibit ROCK2. In preferred aspects, the present invention provides methods for the treatment of GVHD, including chronic GVHD (cGVHD) using compounds having the formulae I-XXV, as set forth herein.
    Type: Application
    Filed: March 11, 2022
    Publication date: December 15, 2022
    Inventors: Alexandra Zanin-Zhorov, Bruce Robert Blazar, Ryan Flynn
  • Treatment of GVHD
    Patent number: 11311541
    Abstract: The invention relates to treatment of graft versus host disease (GVHD) using compounds that inhibit ROCK2. In preferred aspects, the present invention provides methods for the treatment of GVHD, including chronic GVHD (cGVHD) using compounds having the formulae 1-XXV, as set forth herein.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: April 26, 2022
    Assignees: KADMON CORPORATION, LLC, REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Alexandra Zanin-Zhorov, Bruce Robert Blazar, Ryan Flynn
  • TALEN-BASED GENE CORRECTION
    Publication number: 20210187006
    Abstract: The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.
    Type: Application
    Filed: March 4, 2021
    Publication date: June 24, 2021
    Inventors: Mark Osborn, Jakub Tolar, Bruce Robert Blazar, Daniel Voytas
  • TALEN-based gene correction
    Patent number: 10973844
    Abstract: The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: April 13, 2021
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Mark Osborn, Jakub Tolar, Bruce Robert Blazar, Daniel Voytas
  • METHODS OF MAKING, EXPANDING, AND USING A HUMAN PROGENITOR T CELL
    Publication number: 20200308540
    Abstract: A CD7+ progenitor T cell, a method of producing the CD7+ progenitor T cell, and a method of administering the CD7+ progenitor T cell. The method of producing the CD7+ progenitor T cell includes expanding CD34+ cells.
    Type: Application
    Filed: September 28, 2018
    Publication date: October 1, 2020
    Inventors: Heather Emily Stefanski, John Edward Wagner, Jr., Bruce Robert Blazar, Jastaranpreet Singh, Juan Carlos Zúñiga-Pflücker
  • TALEN-BASED GENE CORRECTION
    Publication number: 20190054111
    Abstract: The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.
    Type: Application
    Filed: October 31, 2018
    Publication date: February 21, 2019
    Inventors: Mark Osborn, Jakub Tolar, Bruce Robert Blazar, Daniel Voytas
  • Talen-based gene correction
    Patent number: 10172880
    Abstract: The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: January 8, 2019
    Assignee: Regents of the University of Minnesota
    Inventors: Mark Osborn, Jakub Tolar, Bruce Robert Blazar, Daniel Voytas
  • METHOD FOR EDITING A GENETIC SEQUENCE
    Publication number: 20170175143
    Abstract: This disclosure describes methods, polynucleotides, cells, compositions, and treatment methods that involve channeling a genomic nucleotide sequence. Generally, the method includes introducing a donor polynucleotide and a nucleotide that encodes an enzyme that cuts at least one strand of DNA into a cell that has a genomic sequence in need of editing, allowing the enzyme to cut at least one strand of the genomic sequence, and allowing the donor sequence to replace the genomic sequence in need of editing.
    Type: Application
    Filed: May 20, 2015
    Publication date: June 22, 2017
    Inventors: Jakub Tolar, Bruce Robert Blazar, Daniel Francis Voytas, Mark John Osborn
  • TREATMENT OF GVHD
    Publication number: 20170112832
    Abstract: The invention relates to treatment of graft versus host disease (GVHD) using compounds that inhibit ROCK2. In preferred aspects, the present invention provides methods for the treatment of GVHD, including chronic GVHD (cGVHD) using compounds having the formulae 1-XXV, as set forth herein.
    Type: Application
    Filed: April 9, 2015
    Publication date: April 27, 2017
    Inventors: Alexandra ZANIN-ZHOROV, Bruce Robert BLAZAR, Ryan FLYNN
  • TALEN-BASED GENE CORRECTION
    Publication number: 20160367588
    Abstract: The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.
    Type: Application
    Filed: June 15, 2016
    Publication date: December 22, 2016
    Inventors: Mark Osborn, Jakub Tolar, Bruce Robert Blazar, Daniel Voytas